

**P&T Motion History**  
**Biologic Drugs for Asthma and Urticaria**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
benralizumab <b>dupilumab*</b> mepolizumab omalizumab reslizumab	<p>After considering the evidence of safety, efficacy and special populations for the treatment of asthma, I move that benralizumab, mepolizumab, omalizumab, and reslizumab are safe and efficacious for the treatment of their approved indications. Benralizumab, mepolizumab, and reslizumab can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Figueroa            2<sup>nd</sup>: Chew</p>	October 16, 2019	Yes Storhaug Brown	Yes Storhaug Lee	Passed unanimous

**Bold** = new this update  
 \*grey= not eligible for PDL  
 10/17/2019